<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04263987</url>
  </required_header>
  <id_info>
    <org_study_id>MOLEP Study</org_study_id>
    <nct_id>NCT04263987</nct_id>
  </id_info>
  <brief_title>A Comparison of Traditional and MOSES Laser Enucleation of the Prostate (MOLEP): A Prospective, Randomized, Double-blinded Control Trial A Comparison of Traditional and MOSES Laser Enucleation of the Prostate (MOLEP): A Prospective, Randomized, Double-blinded Control Trial</brief_title>
  <official_title>A Comparison of Traditional and MOSES Laser Enucleation of the Prostate (MOLEP): A Prospective, Randomized, Double-blinded Control Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Vanderbilt University Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Vanderbilt University Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Holmium laser enucleation of the prostate (HOLEP) has proven to be efficacious and safe for
      the treatment of benign prostatic hypertrophy (BPH). New laser technologies such as the Moses
      Pulse laser system provide for improved energy delivery which may decrease blood loss and
      operative time. We seek to evaluate Moses technology for enucleation of the prostate in the
      setting of BPH.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a single-center, prospective, double-blinded, randomized controlled trial comparing
      MOLEP to HOLEP. Inclusion criteria included all symptomatic BPH patients desiring enucleation
      with prostate sizes &gt; 80ccs based on cross-sectional imaging. Patients are randomized in a
      1:1 fashion and the study ispowered to evaluate for a difference in hematocrit change
      postoperatively (i.e. alpha=0.05, for a 50% difference in groups, N=21 per group). All
      surgeries will be performed with a 550 Î¼m fiber. At the start of each case, a laser
      technician would be notified of randomization via envelope and randomize the settings to
      either Moses or traditional mode. The surgeons and patients were blinded to which mode was
      used. All surgeries will be performed using a two lobe technique and laser settings between
      2J and 20-40Hz. Further recorded endpoints include reduction in International Prostate
      Symptom Score (IPSS), improvement in uroflow parameters, and complications postoperatively at
      6 weeks.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 1, 2020</start_date>
  <completion_date type="Anticipated">July 2020</completion_date>
  <primary_completion_date type="Anticipated">May 2020</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Blood Loss</measure>
    <time_frame>postoperative day 1</time_frame>
    <description>Postoperative hematocrit</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Operative time</measure>
    <time_frame>Intraoperatively</time_frame>
    <description>Time for surgery to take place</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">42</enrollment>
  <condition>Benign Prostatic Hyperplasia</condition>
  <arm_group>
    <arm_group_label>Holmium Laser Enucleation of Prostate</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Traditional holmium laser enucleation of the prostate as currently performed</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Moses Holmium Laser Enucleation of Prostate</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>holmium laser enucleation of the prostate as currently performed but with Moses laser settings activated.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Moses laser enucleation of prostate</intervention_name>
    <description>Using the moses settings with the Lumenis laser system to evaluate outcomes for enucleation of the prostate; hypothesis is that it leads to better hemostasis.</description>
    <arm_group_label>Holmium Laser Enucleation of Prostate</arm_group_label>
    <arm_group_label>Moses Holmium Laser Enucleation of Prostate</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Any man with clinical symptoms fo BPH requiring surgery who has a prostate sized at
             greater than 80 grams

        Exclusion Criteria:

          -  Anyone actively on anticoagulation perioperatively
      </textblock>
    </criteria>
    <gender>Male</gender>
    <gender_based>Yes</gender_based>
    <gender_description>For prostatic disease</gender_description>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>nicholas l kavoussi, MD</last_name>
    <phone>443-465-1485</phone>
    <email>nicholas.l.kavoussi@vumc.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Nicole Miller, MD</last_name>
    <phone>4232243933</phone>
    <email>nicole.l.miller@vumc.org</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Vanderbilt University Medical Center</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nicholas Kavoussi, MD</last_name>
      <phone>443-465-1485</phone>
      <email>nicholas.l.kavoussi@vumc.org</email>
    </contact>
    <contact_backup>
      <last_name>Nicole l Miller, MD</last_name>
      <phone>615-322-2880</phone>
      <email>nicole.l.miller@vumc.org</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>February 7, 2020</study_first_submitted>
  <study_first_submitted_qc>February 7, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">February 11, 2020</study_first_posted>
  <last_update_submitted>February 7, 2020</last_update_submitted>
  <last_update_submitted_qc>February 7, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 11, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Vanderbilt University Medical Center</investigator_affiliation>
    <investigator_full_name>Nicholas Kavoussi</investigator_full_name>
    <investigator_title>Clinical Instructor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Hyperplasia</mesh_term>
    <mesh_term>Hyperplasia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

